Aim of the webinar: 

1. To provide an overview of the current state of CAR-T cell therapy and associated apheresis collections
2. To discuss challenges in collections requirements by different commercial entities.
3. To discuss and share experience in dealing with variety of requirements.

Level of education required

Intermediate to advanced

What prior knowledge is required?

We'd recommend you to read the below publications before the webinar

Bobr A, Roberts T, Koepsell S, Williams SM, Schwartz J. Handling the different requirements for commercial and investigational MNC collections by apheresis. Cytotherapy. 2024 Aug;26(8):948-953. Epub 2024 Apr 7. PMID: 38703156. doi: 10.1016/j.jcyt.2024.04.001 https://doi.org/10.1016/j.jcyt.2024.04.001

Liu HD ,Su L, Winters JL, Thibodeaux SR, Park YA, WuY, et al. Considerations for immune effector cell therapy collections: a white paper from the American Society for Apheresis. Cytotherapy 2022;24(9):916–22. https://doi.org/10.1016/j.jcyt.2022.02.007

Worel N, Holbro A, Vrielink H, Ootjers C, Le Poole K, Beer-Wekking I, Rintala T, Lozano M, Bonig H. A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group. Bone Marrow Transplant. 2023 Jul;58(7):742-748. doi: 10.1038/s41409-023-01957-x. Epub 2023 Apr 6. PMID: 37024570 

Target audience

Transfusion Medicine Physicians, Scientists/blood bankers, Nurses, Transfusion practitioners, Transfusion Medicine Educators and Managers

Speakers

Nina Worel

Nina Worel

Specialist for Transfusions Medicine, Medical University of Vienna, Austria

Aleh Bobr

Aleh Bobr

Medical Director, Blood Bank and Tissue Service at University of Nebraska Medical Center, Omaha, NE, USA

Hans Vrielink

Hans Vrielink

Apheresis Subgroup Chair, Specialist in Apheresis Medicine, Sanquin, Amsterdam, The Netherlands